BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9058395)

  • 1. Current concepts of the pathophysiology of migraine.
    Goadsby PJ
    Neurol Clin; 1997 Feb; 15(1):27-42. PubMed ID: 9058395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of 5HT in migraine.
    Buzzi MG
    Cephalalgia; 1999 Sep; 19(7):625-6. PubMed ID: 10524654
    [No Abstract]   [Full Text] [Related]  

  • 3. The biology of serotonin receptors: focus on migraine pathophysiology and treatment.
    Hamel E
    Can J Neurol Sci; 1999 Nov; 26 Suppl 3():S2-6. PubMed ID: 10563226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sumatriptan: efficacy and contribution to migraine mechanisms.
    Pearce JM
    J Neurol Neurosurg Psychiatry; 1992 Dec; 55(12):1103-5. PubMed ID: 1336041
    [No Abstract]   [Full Text] [Related]  

  • 5. Brain stem activation in spontaneous human migraine attacks.
    Weiller C; May A; Limmroth V; Jüptner M; Kaube H; Schayck RV; Coenen HH; Diener HC
    Nat Med; 1995 Jul; 1(7):658-60. PubMed ID: 7585147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of triptans in the treatment of patients with migraine.
    Jamieson DG
    Am J Med; 2002 Feb; 112(2):135-40. PubMed ID: 11835952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5HT1B/1D receptor: a central action in migraine?
    Goadsby PJ; Hoskin KL
    Ann Neurol; 1998 Jun; 43(6):711-8. PubMed ID: 9629840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-HT(1)-like receptor agonists and the pathophysiology of migraine.
    Saxena PR; Ferrari MD
    Trends Pharmacol Sci; 1989 May; 10(5):200-4. PubMed ID: 12722735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buspirone in primary headaches.
    Pascual J; Berciano J
    Acta Neurol Scand; 1998 Feb; 97(2):142. PubMed ID: 9517866
    [No Abstract]   [Full Text] [Related]  

  • 10. 311C90: long-term efficacy and tolerability profile for the acute treatment of migraine. International 311C90 Long-Term Study Group.
    Zagami AS
    Neurology; 1997 Mar; 48(3 Suppl 3):S25-8. PubMed ID: 9071267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of migraine--new insights.
    Hargreaves RJ; Shepheard SL
    Can J Neurol Sci; 1999 Nov; 26 Suppl 3():S12-9. PubMed ID: 10563228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5HT1F- and 5HT7-receptor agonists for the treatment of migraines.
    Agosti RM
    CNS Neurol Disord Drug Targets; 2007 Aug; 6(4):235-7. PubMed ID: 17691977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development.
    Barbanti P; Aurilia C; Egeo G; Fofi L; Palmirotta R
    Expert Opin Investig Drugs; 2017 Mar; 26(3):269-277. PubMed ID: 28103158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy.
    De Vries P; Villalón CM; Saxena PR
    Eur J Pharmacol; 1999 Jun; 375(1-3):61-74. PubMed ID: 10443565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Hydroxyptryptamine 1F (5-HT1F) receptor agonism. A possible new treatment principle for acute migraine attacks.
    Olesen J
    Cephalalgia; 2010 Oct; 30(10):1157-8. PubMed ID: 20855360
    [No Abstract]   [Full Text] [Related]  

  • 16. Serotonin and migraine.
    Humphrey PP; Feniuk W; Perren MJ; Beresford IJ; Skingle M; Whalley ET
    Ann N Y Acad Sci; 1990; 600():587-98; discussion 598-600. PubMed ID: 2252337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is selective 5-HT
    Rubio-Beltrán E; Labastida-Ramírez A; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of serotonin in the pathophysiology of migraine].
    Szczudlik A
    Neurol Neurochir Pol; 1992; Suppl 2():14-27. PubMed ID: 1337765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors.
    Tajti J; Csáti A; Vécsei L
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1509-20. PubMed ID: 25253587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging treatments in headache.
    Diener HC; Gendolla A; Jüptner M; Kaube H; Limmroth V
    Eur Neurol; 1997; 38(3):167-74. PubMed ID: 9363828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.